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Background
Pre-Eclampsia is defined as high blood pressure and
excess protein in the urine after 20 weeks of pregnancy
in a normotensive woman. Even a slight increase in
blood pressure may be a sign of preeclampsia. Despite
extensive clinical trials no therapeutic approaches are
available for either treatment or prevention of pree-
clampsia. Removal of placenta remains the only solution
for resolution of preeclampsia which necessitates prema-
ture deliveries and can have adverse outcomes of low
birth-weight babies, at the same time increasing the risk
of maternal and neonatal mortality and morbidity world-
wide. The concentrations of several placental proteins,
inflammatory cytokines and growth factors are altered in
the maternal circulation of women with preeclampsia.
Nonetheless, early pregnancy screening for preeclampsia
remains insufficient, and randomized controlled trials
that used biomarkers to identify high risk women have
been disappointing, perhaps because the sensitivity of
most of these markers is high in the second or third tri-
mester, long after the placental dysfunction is already
established. At Genetic Centre, GMCH-32,Chandigarh
we have tried to correlate first trimester biochemical and
ultrasonographic markers (viz. Pregnancy Associated
Plasma Protein-A, Placental Growth Factor, Doppler Pul-
satility Index) with establishment of preeclampsia and
other obstetrical complications (fetal growth restriction,
pre-mature delivery, risk of miscarriage, still-birth) in
pregnant women. This study will help in determining the
possible diagnostic utility of PAPPA, PlGF, and Doppler
Pulsatility Index as sensitive and specific biomarkers for
screening early onset of pre-eclampsia.
Materials and methods
All pregnant women visiting Government Medical College
and Hospital, Chandigarh in first trimester of pregnancy
are tested for PAPPA, PlGF, and Doppler Pulsatility Index
after thorough counselling and written informed consent.
PAPPA, PlGF and Doppler Pulsatility Index are quantita-
tively analyzed and multiple of medians are obtained of
approximately 1000 pregnant ladies.
Result and conclusion
In order to relate mode of delivery (NVD/LSCS) with
PAPPA, PlGF, and Doppler Pulsatility Index an initial
sample size of 222 was taken for analysis. The association
of mode of delivery was carried out using chi square test
and it has been observed that PAPPA risk has a signifi-
cant association with mode of delivery however PlGF and
Doppler Pulsatility Index do not have a significant asso-
ciation. However this is an ongoing study and statistical
analysis of more samples is needed to get a significant
association.
Published: 21 January 2014
doi:10.1186/1755-8166-7-S1-O6
Cite this article as: Kaur: Prenatal screening above aneuploidies that is
Pre-Eclampsia. Molecular Cytogenetics 2014 7(Suppl 1):O6.
Correspondence: gurjitkaur123@rediffmail.com
Department of Physiology, Consultant Incharge, Genetic Centre, GMCH-32,
Chandigarh, India
Kaur Molecular Cytogenetics 2014, 7(Suppl 1):O6
http://www.molecularcytogenetics.org/content/7/S1/O6
© 2014 Kaur; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
